Epstein Secrets

ing on `unsustainable drug prices' concludes — Hybrid hearing on `Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM * Tom Lantos Human

arch Associate for Local Policy Ariel Drehobl; University of Michigan School for Environment and Sustainability Assistant Professor Dr Tony Reames; The Foundation for Research on Equal Opportunity Visiting Fellow Robert Bryce; and GRID Alternatives Policy and Regulatory Manager Alexandra Wyatt; 10:00 AM * House Agriculture subcommittee hybrid

ring on `unsustainable drug prices' concludes - Hybrid hearing on Unsustainable Drug Prices: Testimony from the CEOs (Part II); with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

arch Associate for Local Policy Ariel Drehobl; University of Michigan School for Environment and Sustainability Assistant Professor Dr Tony Reames; The Foundation for Research on Equal Opportunity Visiting Fellow Robert Bryce; and GRID Alternatives Policy and Regulatory Manager Alexandra Wyatt; 10:00 AM • House Agriculture subcommittee hybrid

ng on 'unsustainable drug prices' concludes - Hybrid hearing on 'Unsustainable Drug Prices: Testimony from the CEOs (Part II)', with testimony from Amgen CEO Robert Bradway; Mallinckrodt Pharmaceuticals CEO Mark Trudeau; and Novartis U.S. Country President Thomas Kendris; 10:00 AM • Tom Lantos Human

arch Associate for Local Policy Ariel Drehobl; University of Michigan School for Environment and Sustainability Assistant Professor Dr Tony Reames; The Foundation for Research on Equal Opportunity Visiting Fellow Robert Bryce; and GRID Alternatives Policy and Regulatory Manager Alexandra Wyatt; 10:00 AM • House Agriculture subcommittee hybrid